Arroyo-Pérez JA, Estrada-Chávez JJ, Rojo-Medina J

Language: Spanish
References: 16
Page: 83-87
PDF size: 120.76 Kb.

ABSTRACT

Introduction: The prevalence of HBV infection in blood donors have a heterogeneous distribution, in Mexico the donor screening for surface antigen of hepatitis B virus is performed using the third-generation enzyme immunoassay. Material and methods: From January 2003 to December 2006; 756 serum samples from blood donors were screened by the neutralization test. From 1999 to 2008 the frequency of repeatedly reactive samples for HBsAg in mexican blood donors was analyzed. Results: Of 756 samples tested, 442 (58.40%) were positive, 30 (4%) had an indeterminate result and 284 (37.60%) were negative. The frequency of HBV in Mexico declined from 0.48 in 1999 to 0.19 in 2008. Conclusion: Although the frequency of HBV has decreased significantly, the residual risk of transmission of HBV is not eliminated; the tests used in screening donors must be validated for their use in blood bank and must be complemented by the clinical evaluation of the donor.

REFERENCES

1. Lee WM. Hepatitis B virus infection. N Engl J Med 1997; 337: 1733-1745.

2. Zuckerman JN, Zuckerman AJ. Current topics in hepatitis B. J Infect 2000; 41: 130-136.

3. CDC (Centers for Disease Control). FAQs for Health Professionals. Hepatitis B. Disponible en: http: //www.cdc.gov/hepatitis/HBV/HBVfaq.htm#overview. Último acceso el 20 de Julio de 2009.

4. WHO (World Health Organization). Introduction of hepatitis B vaccine into childhood immunization services. Management guidelines, including information for health workers and parents. 2001. p. 4-5.

5. Ropero AM, Danovara HC, Andrus JK. Progress in vaccination against hepatitis B in the Americas. J Clin Virol 2005: 34 (suppl 2): S14-S19.

6. Aiba N, Nishimura H, Arakawa Y, Abe K. Complete nucleotide sequence and phylogenetic analyses of hepatitis B virus isolated from two pileated gibbons. Virus Genes 2003: 27: 219-226.

7. Campos RH, Mbayed VA, Pineiro y Leone FG. Molecular epidemiology of hepatitis B virus in Latin America. J Clin Virol 2005: 34 (suppl 2): S8-S13.

8. Secretaría de Salud. Centro Nacional de la Transfusión Sanguínea. Reporte de resultados del control de calidad externo en serología de la Red Nacional de Laboratorios de Banco de Sangre. México: Secretaría de Salud; 2008. p. 1-10.

9. Vázquez-Flores JA. La seguridad de las reservas sanguíneas en la República Mexicana. Rev Invest Clin 2006; 58(2): 101-108.

10. Levicnik SS. Hepatitis B surface antigen escape mutant in first time blood donor potentially missed by a routine screening assay. Clin Lab 2004; 50: 49-51.

11. Gerlich W. Diagnostic problems caused by HBsAg mutants: a consensus report o fan expert meeting. Intervirology 2004; 47: 310-313.

12. Kleinman et al. Frequency of HBV DNA detection in US blood donors testing positive for the presence of anti-HBc: Implications for transfusion transmission and donor screening. Transfusion 2003; 43: 696-704.

13. Lopez L, Lopez P, Arago A, Rodriguez I, Lopez J. Risk factors for hepatitis B and C in multi-transfused patients in Uruguay. J Clin Virol 2005: 34 (suppl 2): S69-S74.

14. Organización Panamericana de la Salud. Suministro de Sangre para Transfusiones en los Países del Caribe y Latinoamérica en 2006 y 2007: Avance desde 2005 del Plan Regional de Seguridad Transfusional. Washington: OPS; 2009. p. 50.

15. Alvarez do Barrio, González DR, Hernandez SJM, Oyonarte GS. Residual risk of transfusion-transmitted viral infections in Spain, 1997-2002, and impact of nucleic acid testing. Euro Surveill 2005; 10(2): 20-22.

16. Marín y López RA. Hepatitis C seroprevalence in accepted versus deferred blood-donor candidates evaluated by medical history and self-exclusion form. Transfusion 2004; 44: 1344-1349.